Categories: BrainNews

Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Thursday, August 8th at 8:30 a.m. Eastern Time.

Event details follow:
Date: Thursday, August 8th
Time:  8:30 a.m. Eastern Time
Audio Webcast: https://www.CassavaSciences.com/company-presentations
Or  
Audio Webcast: https://edge.media-server.com/mmc/p/zjvmjjcr
   

A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences’ website for 90 days following the webcast.

About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our novel science is based on stabilizing—but not removing—a critical protein in the brain.

For more information, please visit: https://www.CassavaSciences.com

For More Information Contact:
Eric Schoen, Chief Financial Officer
(512) 501-2450 or ESchoen@CassavaSciences.com

Staff

Recent Posts

Tebra Launches AI Note Assist, Reducing Clinical Documentation Time by 50% for Independent Practices

New HIPAA-compliant AI technology integrated into Tebra’s EHR platform reduces documentation time by up to…

2 hours ago

New Multicenter Study Demonstrates SyMRI’s Potential to Transform Clinical Neuroimaging Workflows

LINKÖPING, Sweden, June 3, 2025 /PRNewswire/ -- SyntheticMR AB (publ) is proud to share the…

2 hours ago

Asgard Therapeutics strengthens its Board of Directors and Advisory Board with leading experts in drug development and cancer immunotherapy

Highly experienced biopharma executive Dr Cristina Csimma joins Asgard's Board of Directors, while esteemed immunologists…

2 hours ago

Sixth Global Pharma Company Selects LifeSphere NavaX for GenAI-Driven Case Processing

Top 25 Global Life Science Organization Adopts NavaX, Demonstrating Industry Confidence in Scalable, GenAI-Enabled Technologies…

2 hours ago

CareLineLive Secures Majority Investment from Technology Investment Firm Accel-KKR

LONDON and MENLO PARK, Calif., June 3, 2025 /PRNewswire/ -- CareLineLive, an all-in-one home care…

2 hours ago